Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XJN010 Nasal Spray for Parkinson's Disease Off Episodes
NCT07156773Phase 2Recruiting
- Sponsor
- Novaken
- Start
- Sep 2025
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing XJN010 Nasal Spray with Placebo (2 arms). Primary endpoint: Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part III at Day 14. Started Sep 2025; status: recruiting.
02
Drugs
XJN010
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT07156773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07156773.